Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

McGill University

$17,500.00

Optimizing The Targeting of Acute Myeloid Leukemic Stem Cells With Corticosteroids

EF 2019-20

Résumé
"Acute myeloid leukemia (AML) is a cancer of the blood characterized by an increase in the number of immature blood cells (blasts) in the bone marrow. These blasts cells are derived from abnormal leukemic stem cells (LSCs) and cause the bone marrow to lose its function. Chemotherapies used for AML have stayed the same for the last 30 years and involve extremely intense toxic treatment, yet approximately 40% of AML is resistant to initial treatment or eventually reoccurs. The survival rate 5 years after diagnosis of pediatric AML patients is poor (60%) and accounts for approximately half of leukemic deaths in children. This is due to the chemoresistant nature of the LSCs that sustain the disease. For this reason compounds that specifically target LSCs while sparing normal hematopoietic stem cells (HSCs), which are similar to the LSCs, may significantly improve patient outcome and lower toxicity across a broad leukemia spectrum in adolescent and young adult (AYA) and pediatric patients. After conducting an initial drug screen, our lab has identified corticosteroids as compounds that can target LSCs while sparing HSCs. The goal of this project is to identify other corticosteroids that will target LSCs more effectively than the compounds used for the initial screen, as well as gain insight into the optimal drug design and the mechanism by which corticosteroids target LSCs. Some of the corticosteroids compounds being used for this project have been FDA approved for other treatments and therefore have a high potential to be quickly transferred to the clinic if proven effective."
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
428695
Name
Best Le Ron E
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Optimizing The Targeting of Acute Myeloid Leukemic Stem Cells With Corticosteroids
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Acute Myeloid Leukemia; Corticosteroids; Drug Discovery; Hematology; Leukemic Stem Cells; Mechanism Of Action; Oncology; Pathogenesis; Stem Cell Biology; Therapeutics
Abstract
"Acute myeloid leukemia (AML) is a cancer of the blood characterized by an increase in the number of immature blood cells (blasts) in the bone marrow. These blasts cells are derived from abnormal leukemic stem cells (LSCs) and cause the bone marrow to lose its function. Chemotherapies used for AML have stayed the same for the last 30 years and involve extremely intense toxic treatment, yet approximately 40% of AML is resistant to initial treatment or eventually reoccurs. The survival rate 5 years after diagnosis of pediatric AML patients is poor (60%) and accounts for approximately half of leukemic deaths in children. This is due to the chemoresistant nature of the LSCs that sustain the disease. For this reason compounds that specifically target LSCs while sparing normal hematopoietic stem cells (HSCs), which are similar to the LSCs, may significantly improve patient outcome and lower toxicity across a broad leukemia spectrum in adolescent and young adult (AYA) and pediatric patients. After conducting an initial drug screen, our lab has identified corticosteroids as compounds that can target LSCs while sparing HSCs. The goal of this project is to identify other corticosteroids that will target LSCs more effectively than the compounds used for the initial screen, as well as gain insight into the optimal drug design and the mechanism by which corticosteroids target LSCs. Some of the corticosteroids compounds being used for this project have been FDA approved for other treatments and therefore have a high potential to be quickly transferred to the clinic if proven effective."
Competitiondate
201912
Approvedterm2
1 yr 0 mth
Pinamesdelim
Best, Le Ron E
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~